Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Phase 3 studies demonstrate guselkumab’s efficacy and safety as induction and maintenance therapy for moderate-to-severe Crohn’s disease and ulcerative colitis, with superiority over placebo and favorable safety profiles.
The EASE-CD index offers a reliable, validated, and responsive tool for quantifying Crohn’s disease ulcer activity in clinical trials and practice, improving upon prior endoscopic indices.
Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.